Classification, Functional Stratification and Biomarkers in Ciliopathy (CILLICORIRCM) (CILLICORIRCM)

Classification and Functional Stratification of the Patients With Ciliopathy and Identification of Biomarkers to Improve Their Prognosis

The purpose of the C'IL-LICO RICM study is to develop innovative and transformative diagnostic and prognostic for patients suffering from ciliopathies leading to renal failure.

The objectives is to decipher disease mechanisms and highlight signaling pathways altered in at-risk to develop renal failure patient groups and to produce a prognostic biomarker-based kit to predict the evolution of ciliopathy patients towards renal impairment.

Study Overview

• Status: Recruiting
• Conditions: Ciliopathies; Bardet-Biedl Syndrome; Nephronophthisis; Senior-Loken Syndrome; Joubert Syndrome; Jeune Syndrome
• Intervention / Treatment: Other: Blood sample; Other: Urine sample

Detailed Description

Ciliopathies are a large group of rare and severe genetic diseases caused by ciliary dysfunction, in which nearly all organs can be affected. In spite of being individually rare, they affect collectively up to one per 2000 people. Over the past two decades, more than 90 genes have been reported as mutated in ciliopathy patients. Most proteins encoded by these genes play key roles in the biogenesis or function of cilia, in which they define different functional subdomains. Genetic analyses of ciliopathies revealed a vast clinical variability and a broad genetic heterogeneity as: 1) mutations of the same disease-causing gene can result in distinct clinical entities and, conversely, 2) mutations in several independent genes can lead to similar clinical features, implying both phenotypic and genetic overlaps. The extent and severity of organ involvement may be correlated in part with the nature or location of the mutational event, the cell/tissue specific expression and effect of the mutated protein on cilia dysfunction.

Renal involvement is one of the most frequent manifestations in ciliopathies, and it leads to excessive morbidity and mortality. This includes renal cystic dysplasia (RCD), a kidney developmental defect, and nephronophthisis (NPHP), a chronic tubulointerstitial nephritis, both disorders representing frequent causes of end-stage renal disease (ESRD) during childhood to early adulthood. This makes ESRD a terminal endpoint of either isolated or syndromic ciliopathies, with, hitherto, no available curative treatment of chronic kidney disease whatsoever. The only bearable option is renal transplantation. As the average life-span of a functioning kidney transplant is about 10-15 years, it is urgent to identify therapeutic solutions that slow down progression of CKD in ciliopathies, and delay or avoid dialysis or transplantation. Today, the diagnosis of ciliopathies is first based on primary clinical manifestations, and then confirmed by gene mutation identification. However, even in patients with identified causative mutations, it is impossible to predict the severity of the disease, the risk of appearance (if not present at diagnosis), and/or the rate of progression of CKD. Thus, a crucial issue in the field of ciliopathies is to be able to perform early detection of at-risk patients prior to development of CKD as well as to predict disease progression rate.

• Study Type: Interventional
• Enrollment (Anticipated): 240
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Stanislas LYONNET, MD, PhD; Phone Number: (33) 1 42 75 49 96; Email: stanislas.lyonnet@aphp.fr

Study Locations

• France
  • Paris, France, 75015
    • Recruiting
    • Hopital Necker-Enfants Malades
    • Contact: Stanislas LYONNET, MD, PhD; Phone Number: (33) 1 42 75 49 96; Email: stanislas.lyonnet@aphp.fr

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Child; Adult; Older Adult
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

"Case" Patient :

• with nephronophthisis or ciliopathy with known genetic diagnosis or not
• signed the Informed consent form (patient or legal guardians if minor/incapable major)
• no limit of age, this patients could be recruited from the birth
• social insurance affiliation

Healthy related individual :

• related with a included patient (father, mother, brother, sister)
• signed the Informed consent form (major or legal guardians if minor/incapable major)
• no limit of age, this patients could be recruited from the birth
• social insurance affiliation

"Negative Control" patient :

• without chronic renal failure
• signed the Informed consent form (major or legal guardians if minor/incapable major)
• no limit of age, this patients could be recruited from the birth
• social insurance affiliation

"Positive Control" patient :

• with chronic renal failure not related with a ciliary dysfunction
• signed the Informed consent form (major or legal guardians if minor/incapable major)
• no limit of age, this patients could be recruited from the birth
• social insurance affiliation

Exclusion Criteria "Case" Patient :

• pregnant, parturious and nursing mothers.
• with functional renal graft
• use an experimental treatment during 30 days before inclusion date

Healthy related individual :

- pregnant, parturious and nursing mothers.

"Negative Control" patient :

- pregnant, parturious and nursing mothers.

"Positive Control" patient :

• pregnant, parturious and nursing mothers.
• with functional renal graft
• use an experimental treatment during 30 days before inclusion date

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Diagnostic
• Allocation: Non-Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

4

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Other: "Case" Patient; Patient with ciliopathy	Other: Blood sample; Blood sample of 15ml max by subject (case, related individual, control) once time: subject less than 5 kg : 1.8 to 4.5 ml max; subject 5 kg to 10 kg : 4.5 to 9 ml max; subject 10 kg to 15 kg : 9 to 13.5 ml; subject 15 kg to 20 kg : 13.5 to 15 ml max; Other: Urine sample; Urine sample (500 ml) once time
Other: Healthy related individual; Individual without ciliopathy but related to a patient with ciliopathy (father, mother, brother, sister)	Other: Blood sample; Blood sample of 15ml max by subject (case, related individual, control) once time: subject less than 5 kg : 1.8 to 4.5 ml max; subject 5 kg to 10 kg : 4.5 to 9 ml max; subject 10 kg to 15 kg : 9 to 13.5 ml; subject 15 kg to 20 kg : 13.5 to 15 ml max; Other: Urine sample; Urine sample (500 ml) once time
Other: "Negative Control" patient; patient without renal disease	Other: Blood sample; Blood sample of 15ml max by subject (case, related individual, control) once time: subject less than 5 kg : 1.8 to 4.5 ml max; subject 5 kg to 10 kg : 4.5 to 9 ml max; subject 10 kg to 15 kg : 9 to 13.5 ml; subject 15 kg to 20 kg : 13.5 to 15 ml max; Other: Urine sample; Urine sample (500 ml) once time
Other: "Positive Control" patient; patient with renal disease other that ciliopathy but with a similar renal function to the ciliopathy group ("case" patient)	Other: Blood sample; Blood sample of 15ml max by subject (case, related individual, control) once time: subject less than 5 kg : 1.8 to 4.5 ml max; subject 5 kg to 10 kg : 4.5 to 9 ml max; subject 10 kg to 15 kg : 9 to 13.5 ml; subject 15 kg to 20 kg : 13.5 to 15 ml max; Other: Urine sample; Urine sample (500 ml) once time

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in transcriptional profiles in different subtypes of ciliopathy patients and control subjects	RNA-sequencing analysis will be utilized to identify changes in transcriptional profiles and biological pathways in subgroups of patients to research whether the target mutation gene combination analyzed by transcription group was consistent with clinical cell morphological diagnosis and disease progression. Different human models will be used: Urine-derived Renal Epithelial Cells (URECs), renal organoids from patients derived induced Pluripotent Stem Cells (iPSCs) and urines.	3 years

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in proteome profiles in different subtypes of ciliopathy patients and control subjects	Proteomics analysis will be utilized to identify changes in proteome profiles in subgroups of patients to research whether the target mutation gene combination analyzed by proteomics group was consistent with clinical cell morphological diagnosis and disease progression. Different human models will be used: Urine-derived Renal Epithelial Cells (URECs), renal organoids from patients derived induced Pluripotent Stem Cells (iPSCs) and urines.	3 years
Change in metabolome profiles in different subtypes of ciliopathy patients and control subjects	Metabolomics analysis will be utilized to identify changes in metabolome profiles in subgroups of patients to research whether the target mutation gene combination analyzed by metabolomics group was consistent with clinical cell morphological diagnosis and disease progression. Different human models will be used: Urine-derived Renal Epithelial Cells (URECs), renal organoids from patients derived induced Pluripotent Stem Cells (iPSCs) and urines.	3 years

Collaborators and Investigators

• Sponsor: Assistance Publique - Hôpitaux de Paris
• Investigators: Study Chair: Sophie SAUNIER, PhD, Imagine Institute

Study record dates

Study Major Dates

• Study Start (Actual): November 8, 2021
• Primary Completion (Anticipated): November 1, 2024
• Study Completion (Anticipated): November 1, 2024

Study Registration Dates

• First Submitted: March 31, 2021
• First Submitted That Met QC Criteria: April 30, 2021
• First Posted (Actual): May 6, 2021

Study Record Updates

• Last Update Posted (Actual): October 31, 2022
• Last Update Submitted That Met QC Criteria: October 28, 2022
• Last Verified: October 1, 2022

More Information

Terms related to this study

• Keywords: Chronic Kidney Disease; Pediatrics; Biomarkers; Ciliopathies; Genetic diseases
• Additional Relevant MeSH Terms: Pathologic Processes; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Eye Diseases; Disease; Congenital Abnormalities; Genetic Diseases, Inborn; Hypothalamic Diseases; Eye Diseases, Hereditary; Abnormalities, Multiple; Retinitis Pigmentosa; Syndrome; Bardet-Biedl Syndrome; Laurence-Moon Syndrome; Ciliopathies
• Other Study ID Numbers: APHP200896; ID-RCB Number (Other Identifier: 2020-A02576-33)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No